U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Silver

    23.14
    -0.40 (-1.70%)
     
  • EUR/USD

    1.1320
    +0.0108 (+0.96%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3338
    +0.0018 (+0.14%)
     
  • USD/JPY

    113.3300
    -2.0090 (-1.74%)
     
  • BTC-USD

    54,650.30
    +458.31 (+0.85%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

BridgeBio Pharma's Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has granted Fast Track Designation to BridgeBio Pharma Inc's (NASDAQ: BBIO) BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i).

  • This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received this year.

  • Clinical trials to verify the safety and efficacy of BBP-418 are ongoing.

  • BBP-418 has received Orphan Drug Designation for the treatment of LGMD2i from the FDA and LGMD from the European Medicines Agency.

  • LGMD2i is a monogenic autosomal recessive disease caused by partial loss of function mutations in the FKRP gene. These FKRP mutations impair glycosylation of α-DG, a protein associated with stabilizing muscle cells.

  • Related Link: FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: BBIO shares are up 2.61% at $50.00 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.